Polyrizon Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
PLRZ
- Share Price
-
$0.56
- (As of Friday Closing)
Polyrizon General Information
Description
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
Contact Information
Website
www.polyrizon-biotech.comCorporate Office
- HaTidhar Street
- Raanana 4366507
- Israel
Corporate Office
- HaTidhar Street
- Raanana 4366507
- Israel
Polyrizon Stock Performance
As of 21-Mar-2025, Polyrizon’s stock price is $0.56. Its current market cap is $2.45M with 4.39M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.56 | $0.56 | $0.51 - $4.80 | $2.45M | 4.39M | 536K | -$0.50 |
Polyrizon Financials Summary
As of 31-Dec-2024, Polyrizon has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 9,478 | 9,478 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (1,427) | (1,427) | (596) | (774) |
| Net Income | (1,545) | (1,545) | (600) | (779) |
| Total Assets | 5,547 | 5,547 | 559 | 546 |
| Total Debt | 0 | 0 | 200 | 622 |
Polyrizon Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Polyrizon Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Polyrizon Patents
Polyrizon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024532611-A | Mucoadhesive polymers for nasal drug delivery | Pending | 31-Aug-2021 | ||
| EP-4395741-A1 | Mucoadhesive polymers for nasal drug delivery | Pending | 31-Aug-2021 | ||
| US-20240358741-A1 | Mucoadheslve polymers for nasal drug delivery | Pending | 31-Aug-2021 | ||
| US-8679484-B2 | Method for removal of toxins from mucosal membranes | Inactive | 02-Mar-2005 | ||
| US-20140147452-A1 | Method for removal of toxins from mucosal membranes | Inactive | 02-Mar-2005 | A61K47/61 |
Polyrizon Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Polyrizon Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Polyrizon FAQs
-
When was Polyrizon founded?
Polyrizon was founded in 2005.
-
Where is Polyrizon headquartered?
Polyrizon is headquartered in Raanana, Israel.
-
What is the size of Polyrizon?
Polyrizon has 2 total employees.
-
What industry is Polyrizon in?
Polyrizon’s primary industry is Biotechnology.
-
Is Polyrizon a private or public company?
Polyrizon is a Public company.
-
What is Polyrizon’s stock symbol?
The ticker symbol for Polyrizon is PLRZ.
-
What is the current stock price of Polyrizon?
As of 21-Mar-2025 the stock price of Polyrizon is $0.56.
-
What is the current market cap of Polyrizon?
The current market capitalization of Polyrizon is $2.45M.
-
What is Polyrizon’s annual earnings per share (EPS)?
Polyrizon’s EPS for 12 months was -$0.50.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
